Andrew Joseph Muir, MD

Professor of Medicine
Chief, Division of Gastroenterology in the Department of Medicine
Member in the Duke Clinical Research Institute
Campus mail 03137B Hosp South, Durham, NC 27710
Phone (919) 684-2052
Email address andrew.muir@duke.edu
  • Hepatitis C 
  • Primary sclerosing cholangitis
  • Cirrhosis
  • Liver Transplantation
  • Clinical Trials
  • Healthcare disparities in liver disease 
  • Outcomes Research
In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Duke University, 1998 - 2000
  • Chief Medical Resident, Medicine, Duke University, 1997 - 1998
  • Fellow in Gastroenterology, Medicine, Duke University, 1996 - 1997
  • Medical Resident, Medicine, Duke University, 1993 - 1996
  • M.H.S., Duke University, 2001
  • M.D., Duke University, 1993

Publications

Curry, MP, O'Leary, JG, Bzowej, N, Muir, AJ, Korenblat, KM, Fenkel, JM, Reddy, KR, Lawitz, E, Flamm, SL, Schiano, T, Teperman, L, Fontana, R, Schiff, E, Fried, M, Doehle, B, An, D, McNally, J, Osinusi, A, Brainard, DM, McHutchison, JG, Brown, RS, Charlton, M, and ASTRAL-4 Investigators, . "Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis." The New England Journal of Medicine 373, no. 27 (December 2015): 2618-2628.

PMID
26569658
Full Text

Charlton, MR, O'Leary, JG, Bzowej, NH, Muir, AJ, Korenblat, KM, Fenkel, JM, Reddy, KR, Lawitz, E, Schiano, TD, Teperman, LW, Fontana, RJ, Schiff, ER, Fried, MW, Doehle, B, An, D, McNally, J, Osinusi, A, Brainard, DM, McHutchison, JG, Brown, RS, and Curry, MP. "Sofosbuvir/Velpatasvir Fixed Dose Combination For The Treatment Of HCV In Patients With Decompensated liver Disease: The Phase 3 ASTRAL-4 Study." December 2015.

Scholars@Duke

Wilder, JM, and Muir, AJ. "Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes." Therapeutic advances in chronic disease 6, no. 6 (November 2015): 314-327. (Review)

PMID
26568808
Full Text

Muir, AJ, and Naggie, S. "Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association 13, no. 12 (November 2015): 2166-2172. (Review)

PMID
26192145
Full Text

Mayo, MJ, Wigg, AJ, Thompson, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Muir, AJ. "Impact of NGM282 on the Incidence and Severity of Pruritus in Primary Biliary Cirrhosis Patients and Correlations with Liver Chemistries and Serum Bile Acids." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.

Scholars@Duke

Mayo, MJ, Wigg, AJ, Thompson, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Muir, AJ. "Impact of NGM282 on the Incidence and Severity of Pruritus in Primary Biliary Cirrhosis Patients and Correlations with Liver Chemistries and Serum Bile Acids." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.

Scholars@Duke

Mayo, MJ, Wigg, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, Muir, AJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Thompson, AJ. "NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.

Scholars@Duke

Mayo, MJ, Wigg, AJ, Roberts, SK, Arnold, H, Hassanein, TI, Leggett, BA, Bate, JP, Weltman, M, Carey, EJ, Muir, AJ, McCaughan, G, Bollipo, SJ, Gordon, SC, Angus, PW, Riordan, S, Shiffman, ML, Young, E, Ling, L, Luo, J, Elliott, M, Rossi, S, DePaoli, AM, and Thompson, AJ. "NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial." 66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD). San Francisco, CA. November 13, 2015 - November 17, 2015.: WILEY-BLACKWELL, October 1, 2015.

Scholars@Duke

Reau, N, Muir, AJ, Pockros, P, Reddy, KR, Pedrosa, M, Larsen, L, Enejosa, J, and Howell, C. "High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended Regimen of Ombitasvir/Paritaprevir/r plus Dasabuvir +/- Ribavirin: Integrated Safety and Efficacy Analysis." October 2015.

Scholars@Duke

Harrison, SA, Goodman, ZD, Ratziu, V, Loomba, R, Diehl, AM, Lawitz, E, Hinrichsen, H, Bambha, K, Abdelmalek, MF, Myers, RP, Schall, REA, Subramanian, M, McHutchison, JG, Afdhal, NH, and Muir, AJ. "Serum lysyl oxidase-like-2 (sLOXL2) levels correlate with fibrosis stage in patients with nonalcoholic steatohepatitis (NASH)." October 2015.

Scholars@Duke

Pages